RNA Therapeutics Beyond mRNA

The COVID-19 pandemic thrust messenger RNA (mRNA) vaccines into the global spotlight, demonstrating that RNA-based therapeutics could be developed, manufactured, and deployed at unprecedented speed. But mRNA represents just one chapter in the RNA therapeutics story. A broader revolution is underway, with multiple RNA modalities advancing through clinical development and opening new therapeutic possibilities.

The RNA Therapeutic Landscape

According to research published in PubMed, synthetic RNA therapeutics encompass multiple modalities including mRNA, microRNA (miRNA), antisense oligonucleotides (ASOs), small interfering RNA (siRNA), and circular RNA (circRNA). Each offers distinct advantages for different therapeutic applications, creating a rich toolkit for drug developers.

The main advantages of RNA-based modalities are high flexibility in designing RNA sequences and rapid production for clinical screening. In the era of precision medicine, RNA-based therapeutic approaches potentially constitute suitable platforms for targeting heterogeneous tumours that possess multiple sub-clonal cancer cell populations.

Beyond Gene Silencing: The Mechanistic Diversity

While siRNA and ASOs primarily work by reducing expression of disease-causing genes, the RNA therapeutic toolkit is far more versatile. According to a comprehensive review in Biochimica et Biophysica Acta, the ability of a single non-coding RNA to modulate the expression of multiple downstream gene targets and associated pathways provides a rationale to pursue them for therapeutic drug development.

MicroRNAs, for example, have emerged as key players in regulating important growth regulatory pathways in cancer pathogenesis. Early data from pre-clinical studies have demonstrated that synthetic miRNA-based therapeutic molecules, along with various protective coating approaches, allow for efficient delivery and anti-tumour activity. Some miRNA-based cancer therapeutic strategies have shown promising results in early-phase human clinical trials.

The Rise of Circular RNA

Circular RNAs represent one of the most exciting frontiers in RNA therapeutics. Unlike linear RNA, circRNAs form closed loops that resist degradation by cellular exonucleases, potentially enabling longer duration of therapeutic effect. Research has shown that circRNAs can function as "sponges" for microRNAs, sequestering them and thereby regulating downstream gene expression.

Research published in Theranostics demonstrates circRNAs' role in disease. Studies have shown circRNA-ZBTB44, for example, is significantly upregulated in pathological neovascularization and can act as a miRNA sponge to regulate vascular endothelial growth factor expression. This mechanistic understanding opens therapeutic opportunities in diseases characterised by aberrant angiogenesis.

The Delivery Challenge

For all RNA modalities, delivery remains the critical challenge. RNA molecules are inherently unstable and struggle to cross cell membranes without assistance. The field has made significant progress through multiple approaches.

According to research in the Journal of Nanobiotechnology, exosomes have emerged as promising delivery vehicles. These naturally occurring extracellular vesicles have characteristics of good biocompatibility, low toxicity and immunogenicity, and great designability. As therapeutic carriers, they enable delivery of DNA, mRNA, miRNA, siRNA, circRNA, and other nucleic acids.

Lipid nanoparticles (LNPs), validated by the COVID-19 mRNA vaccines, have also proven effective for hepatic delivery. However, targeting tissues beyond the liver remains an active area of research, with companies developing next-generation delivery technologies to enable RNA therapeutics for a broader range of diseases.

Oncology: A Key Application Area

Cancer represents perhaps the most compelling application for RNA therapeutics. The heterogeneity of tumours, driven by multiple genetic alterations and resistance mechanisms, is well-suited to approaches that can address multiple targets simultaneously.

Research from the Journal of Pharmacology and Experimental Therapeutics notes that combination approaches of RNA therapeutics with cancer immunotherapy show particular promise. The ability to modulate tumour microenvironment while simultaneously targeting cancer cells creates opportunities for synergistic effects.

Investment Implications

We see several compelling opportunities in the RNA therapeutics space:

Platform Versatility: Companies with validated delivery platforms that can be applied across multiple RNA modalities offer diversified pipelines and partnership opportunities.

Next-Generation Modalities: CircRNA and other emerging modalities are earlier stage but offer potential advantages in stability and manufacturing that could prove transformative.

Delivery Innovation: The delivery bottleneck creates opportunities for companies developing extra-hepatic targeting solutions. Success here would dramatically expand the addressable market for RNA therapeutics.

Combination Strategies: Companies developing RNA therapeutics designed for combination with checkpoint inhibitors and other immunotherapies are positioned to address the limitations of current cancer treatments.

Looking Ahead

The RNA therapeutics field continues to evolve rapidly. With advances in delivery technology, manufacturing scale-up, and clinical validation, we anticipate RNA-based medicines will become increasingly important tools for addressing diseases that have resisted traditional approaches. The diversity of modalities, each with distinct mechanisms and therapeutic applications, creates a rich landscape for innovation and investment.